TNBCs do not express or under-express ER, PR or HER2 and represents 12% of the breast cancers and about 75–90% of basal-like breast cancers[10, 12] that are peculiarly therapy resistant in nature[13, 14]. This evidence concerns the gene ERBB2 and breast carcinoma.